Article
CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers.
Acta pharmacologica Sinica - 1 Oct 2022
Cao Jiang-Yan, Qi Shuang, Wu Hong, Wang Ao-Li, Liu Qing-Wang, Li Xi-Xiang, Wang Bei-Lei, Ge Juan, Zou Feng-Ming, Chen Cheng, Wang Jun-Jie, Hu Chen, Liu Jing, Wang Wen-Chao, Liu Qing-Song
Abstract excerpt
Oncogene HER2 is amplified in 20%-25% of human breast cancers and 6.1%-23.0% of gastric cancers, and HER2-directed therapy significantly improves the outcome for patients with HER2-positive cancers. However, drug resistance is still a clinical challenge due to primary or acquired mutations and drug-induced negative regulatory feedback. In this study, we discovered a potent irreversible HER2 kinase inhibitor,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.